摘要
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a chronic inflammatory disorder in the gastrointestinal tract with a rapidly increase global incidence.1 It is now well-established that the abnormal alteration of gut microbiome, commonly referred to microbial dysbiosis, is closely associated with IBD development.2 For instance, the depletion of beneficial commensals such as Clostridium and Lactobacillus as well as their derived metabolites has been frequently observed in patients with IBD. To date, there are lots of publications studying the alteration of gut microbiome and/or metabolome in IBD. However, the gut microbiome is readily influenced by various environmental factors including diet, drugs, ethnicity, and geographical population.3 As a consequence, diverse and controversial results are reported among different studies. It is therefore of importance to summarize the findings from multiple studies, thereby minimizing the impact of inter-study variation and allowing the identification of microbes and metabolites with the most significant association with IBD. In this issue of Journal of Gastroenterology and Hepatology, Upadhyay et al. conducted a literature review on publications using amplicon sequencing to profile the gut microbiome in patients with IBD.4 Several microbial taxa that are consistently altered in IBD patients from different studies, were identified in this article. This includes the enrichment of opportunistic pathobionts including Fusobacterium and Streptococcus are enriched in IBD patients, as well as the depletion of beneficial commensals such as Clostridium, Lactobacillus, and Roseburia.5, 6 Upadhyay et al. also reported that there is no significant difference in microbiome composition between UC and CD patients.7 Of note, some microbial taxa including Bacteroides were found to have opposing changes across studies.6, 8 This may be due to the low resolution of amplicon sequencing, of which it cannot characterize microbial taxa at species level. For Bacteroides species, some of them are known probiotics (e.g. B. fragilis) while the others can be potentially pathogenic (e.g. B. ovatus). To allow comprehensive characterization, it is necessary to conduct metagenomic sequencing which has a higher taxonomical resolution, thereby facilitating identification at species or even strain level. Apart from the microbes themselves, their derivatives also play a role in inflammation. A classic example is the correlation between high-fat diet and IBD, of which the high content of dietary lipids impairs the gut barrier with increased intestinal permeability.9 This allows bacterial endotoxins particularly lipopolysaccharides to have easier access into the bloodstream, causing systemic inflammation and imbalance of lipid metabolism. An increased triglyceride level could also result in gut microbial dysbiosis.10 Consistently, Upadhyay et al. revealed the decrease of various lipid metabolites in IBD patients from different studies, implicating their reduced capability to metabolize dietary lipids.4 Of note, lipid metabolites are known to have dual roles in inflammation, especially the contrasting immunomodulatory role between monounsaturated and polyunsaturated fatty acids.11 Such complex mechanisms may therefore explain the ineffectiveness of supplementing long-chain fatty acids to treat IBD patients.12 It is also noteworthy that literatures included in the study by Upadhyay et al. profiled metabolites in different sample types (feces, serum, plasma, or colon mucosa), which may in turn lead to the inter-study variation of results.4 In comparison, the role of short-chain fatty acids (SCFAs) in IBD is less controversial. SCFAs are produced by gut bacteria during the fermentation of non-digestible polysaccharides. Acetate, propionate, and butyrate are the three most common SCFAs and they are all crucially involved in the maintenance of intestinal homeostasis. SCFAs also interact with colon epithelial cells to activate a cascade of anti-inflammatory signaling pathways.13 Indeed, Upadhyay et al. confirmed the consistent depletion of SCFAs in IBD patients from multiple studies.4 Similarly, some preclinical studies reported that SCFAs particularly butyrate could directly suppress the production of pro-inflammatory cytokines from neutrophils and other immune cells, thus suggesting the therapeutic potential of SCFA supplementation against IBD.14 Meanwhile, Upadhyay et al. also examined the abundance of amino acids including phenylalanine, leucine, valine, and lysine in IBD patients, yet their changes are greatly varied across studies.4 Such disparity may attribute to the lack of investigation on the alteration of a specific amino acid in IBD. Further studies are warranted to depict the role and mechanistic association of different amino acids with chronic inflammation. To wrap up this article, Upadhyay et al. highlighted that there is still a huge gap between the identified metabolites and their actual roles in IBD. Likewise, it remains elusive whether these microbial changes are the cause or consequence of persistent inflammation. In that case, integrated analysis on the gut microbiome and metabolome should be considered to fully unravel their mechanisms in IBD. For example, the consistent depletion of SCFAs and their bacterial producers in IBD patients therefore testifies their anti-inflammatory functions in humans. With the advance in metagenomic and metabolomic profiling, it is feasible to have a deeper understanding on the intricate relationship among gut microbes, metabolites, and the host. In addition, Upadhyay et al. also pinpointed the necessity of validation by targeted metabolomic analysis, which undoubtedly can reduce controversial findings among studies. Together, on top of the tremendous efforts that have been invested, in-depth mechanistic investigations rather than characterization of the gut microbiome and metabolome in IBD should now be of focus, thereby reducing the global socioeconomic burden brought by this disease.